1.1 List of Tables
1.2 List of Figures

2 Spinal Muscular Atrophy: Executive Summary
2.1 Uptake of New Products to Drive Robust Growth Within the SMA Market
2.2 Biogen to Lose its Monopoly of the SMA Market
2.3 Unmet Needs Remain High Despite Approval of First Disease-Modifying Therapy
2.4 Zolgensma and Risdiplam Demonstrate Greatest Potential in SMA
2.5 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of SMA
5.5 Epidemiological Forecast for SMA for Growth Markets (2018-2028)
5.5.1 Diagnosed Prevalent Cases of SMA
5.5.2 Sex-Specific Diagnosed Prevalent Cases of SMA
5.5.3 Diagnosed Prevalent Cases of SMA by Type
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis

6 Current Treatment Options
6.1 Overview

7 Unmet Needs and Opportunity Assessment in APAC

8 R&D Strategies in APAC

9 Pipeline Assessment in APAC
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

11 Appendix

List of Tables
Table 1: SMA: Key Metrics in the 5GM in APAC
Table 2: Clinical Classification of SMA
Table 3: Risk Factors and Comorbidities for SMA
Table 4: Treatment Guidelines for SMA
Table 5: Leading Treatments for SMA, 2019
Table 6: Clinical Trials for Zolgensma (Onasemnogene Abeparvovec-xioi), 2019
Table 7: Clinical Trials for Risdiplam, 2019
Table 8: Clinical Trials for Valproate Sodium, 2019
Table 9: Comparison of Therapeutic Classes in Development for SMA, 2018-2028
Table 10: Clinical Benchmark of Key Pipeline Drugs - SMA
Table 11: Commercial Benchmark of Key Pipeline Drugs - SMA
Table 12: Key Events Impacting Sales for SMA, 2018-2028
Table 13: SMA Market - Global Drivers and Barriers, 2018-2028
Table 14: Key Historical and Projected Launch Dates for SMA
Table 15: Key Historical and Projected Patent Expiry Dates for SMA
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for SMA in 2018 and 2028
Figure 2: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of SMA During the Forecast Period
Figure 3: The Difference Between SMN1 and SMN2 Genes and the Molecular Basis of SMA
Figure 4: Diagnostic Evaluation for SMA
Figure 5: 5GM, Diagnosed Prevalence of SMA, %, Both Sexes, All Ages, 2018
Figure 6: 5GM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of SMA
Figure 7: 5GM, Diagnosed Prevalent Cases of SMA, N, Both Sexes, All Ages, 2018
Figure 8: 5GM, Sex-Specific Diagnosed Prevalent Cases of SMA, N, All Ages, 2018
Figure 9: 5GM, Diagnosed Prevalent Cases of SMA by Type, N, Both Sexes, All Ages, 2018
Figure 10: Unmet Needs and Opportunities in SMA
Figure 11: Overview of the Development Pipeline SMA
Figure 12: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Licensed for SMA in the 5GM During the Forecast Period
Figure 13: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Spinraza
Figure 14: 5GM Sales Forecast by Country for SMA in 2018 and 2028
Figure 15: Sales Forecast by Product for SMA in India in 2028
Figure 16: Sales Forecast by Product for SMA in China in 2018 and 2028
Figure 17: Sales Forecast by Product for SMA in Australia in 2018 and 2028
Figure 18: Sales Forecast by Product for SMA in South Korea in 2018 and 2028
Figure 19: Sales Forecast by Products for SMA in Japan in 2018 and 2028

Companies Mentioned
- Allen & Hanburys
- AveXis
- Biogen
- GlaxoSmithKline
- Ionis
- Kowa Co
- Novartis
- PTC Therapeutics
- Rhone-Poulenc Rorer
- Roche
- Sanofi
- SMA Foundation